NEW YORK (GenomeWeb) – B Braun Medical US and Tuebingen, Germany-based CeGaT today announced the launch of a US company offering next-generation sequencing-based diagnostics.

The new firm called B Braun CeGaT is based in B Braun Medical's headquarters in Bethlehem, Pa. and will offer CeGaT's diagnostic panels for evaluating all the genes that are associated with a patient's phenotype. The technology was launched in 2010 and is being made available in the US with the establishment of B Braun CeGaT.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.